Navigation Links
Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace
Date:2/18/2009

LA JOLLA, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has submitted to the U.S. Food and Drug Administration (FDA) an amended Phase 3 protocol for ATPace to be reviewed as a Special Protocol Assessment (SPA). The amendment addresses written comments recently received from the FDA in response to the Company's initial SPA submission to the FDA on November 20, 2008.

To address the FDA's main comments, Cordex has changed the design of the pivotal clinical trial as follows:

               (1) To demonstrate drug efficacy and establish an optimal
                   dose-regimen: A parallel four-arm trial design will consist
                   of three doses of ATPace (5, 10, and 20 mg) and placebo.
               (2) To demonstrate drug safety: The number of studied patients
                   receiving the initial dose per proposed drug's label has
                   been increased to 100.

Amir Pelleg, Ph.D., Cordex's President and Chief Scientific Officer commented, "We are very pleased with the FDA's timely response to our initial ATPace SPA submission. We now believe that the written correspondence from the FDA, which clearly outlines all study-design requirements and clinical endpoints, would enable us to generate the efficacy and safety data required for the marketing approval of ATPace. We look forward to initiating the pivotal Phase 3 clinical trial for ATPace in PSVT patients."

Cordex will host a teleconference on Friday, February 20, at 10:00 a.m. EST to provide a fourth quarter business review and drug development update including a discussion of this SPA submission. Cordex's Chief Executive Officer, James S. Kuo, M.D., M.B.A., will give the presentation and there will be a question-and-answer session immediately afterwards.

To participate in the teleconference, please call toll-free 800.894.5910 (direc
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cordex Pharma Sets Fourth Quarter 2008 Program Update Call
2. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
3. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
4. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
5. National Pharmaceutical Council on Economic Stimulus Package: Comparative Effectiveness Research Funding Should Target Improvements in Quality of Patient Care
6. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
7. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
8. WuXi PharmaTech Announces CFO Benson Tsang to Leave Company; COO Edward Hu Named Acting CFO
9. Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
10. Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series
11. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... 2015 , ... A recent survey by the National ... believe people can positively affect their diabetes, few look beyond diet changes to ... changes was important. Far fewer participants mentioned the need for exercise (30%), maintaining ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... and amputation , AUGUST 3, 2015 – Since winning a South by Southwest® ... Not Impossible – an organization whose mission is to develop technology for the ...
(Date:8/3/2015)... ... 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and ... Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker ... the Company’s presentation may be accessed via the investor relations section of the Company’s ...
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris A. Baldwin, ... Room – Gilbert, opening in August. The new facility is licensed under ... Valley. , “Dr. Baldwin is an excellent leader and will ensure our new ...
Breaking Medicine News(10 mins):Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... highlighted, MCLEAN, Va., Sept. 14 As part of ... the USA",25- week charity program that highlights a different charity ... 30th and continued each Friday as USA TODAY,thanked America for ... generosity. USA TODAY has selected 25 charities and has celebrated,the ...
... scientists recently discovered an association between being overweightand a ... This discovery was published in the Sept. 14 issue ... group led by Dr. Corazziari from the University La ... in the field of gastroenterology for a long time ...
... risk of genetic condition that can lead to early ... simple blood test early in life could identify children ... cholesterol levels and greatly increases the risk of early ... Drug treatment could eventually be started to reduce that ...
... of your level of,expertise, you will have a lot to ... Do you know: The essential DNA for quality ... How to exploit process and quality for competitive advantage? ... How to achieve product innovation excellence? The benefits ...
... Inc. (Nasdaq: MTMD ) announced today that ... under the Hart-Scott-Rodino Antitrust,Improvements Act of 1976, as ... Microtek Medical Holdings, Inc. The Boards of,Directors for ... expected to close during the fourth quarter of ...
... With In-depth Information on,Injured Players, ALEXANDRIA, Va., ... as the real-life games, enthusiasts can now look,to ... for a,better understanding of the injuries plaguing their ... Bell, PT, MS, OCS,CSCS, has joined ESPN.com as ...
Cached Medicine News:Health News:USA TODAY Concludes 'Spirit of the USA' Charity Program as Part of Newspaper's 25th Anniversary Celebration 2Health News:USA TODAY Concludes 'Spirit of the USA' Charity Program as Part of Newspaper's 25th Anniversary Celebration 3Health News:Screening Proposed for Childhood Cholesterol Levels 2Health News:Screening Proposed for Childhood Cholesterol Levels 3Health News:Quality Innovators to Network in Atlanta Sept. 19-21: Learn from Those Who Got It Right 2Health News:Microtek Medical Receives Early Termination of Hart-Scott-Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab 2Health News:Microtek Medical Receives Early Termination of Hart-Scott-Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab 3Health News:Physical Therapist Provides Injury Analysis for Fantasy Football 2
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Sorrento ... that it has entered into an exclusive licensing agreement ... or biobetter antibodies from Mabtech Limited, a holding company ... China . Under the ... these 4 monoclonal antibodies (mAbs) for the North American, ...
(Date:7/31/2015)... , July 31, 2015  Physicians and payers ... the biopharmaceutical market. Patients are better informed and ... and switching therapies. This shift in power is ... efforts toward patient-focused marketing. As part ... have learned it,s important to educate, communicate and ...
(Date:7/31/2015)... MOUNT PROSPECT, Ill. , July 31, 2015 ... of Pharmacy ® (NABP ® ) issued ... charged with ensuring that action is taken against ... the Internet Drug Outlet Identification Program ... 2015 , thousands of websites ...
Breaking Medicine Technology:Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3
With the sample processing core unit and intelligent process management, combines a wide variety of analytical modules to enable full consolidation of clinical chemistry and immunochemistry....
... Diagnostics Task Targeted Automation VS ... automation of pre- and post-analytical ... sorting / archiving of primary ... code labeled secondary tubes. Fully ...
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
... and gain efficiency in the lab ... (LAS), the high-throughput aliquotting solution with ... Olympus OLA2500 LAS is an advanced ... to high-volume laboratories. As a front-end ...
Medicine Products: